Newsroom

Director/Sr. Director of Gene Transfer Technologies

Philadelphia, PA

Cabaletta Bio is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Cabaletta’s therapeutic platform produces highly selective autologous Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The platform is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop the CAAR T technology to treat B cell-mediated autoimmune diseases. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris (mPV), which is a rare skin disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects.

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing a new type of therapy, where patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that success in the Cabaletta mission lies in the hands of individuals across every aspect of the company. To nurture this, we make an active commitment to the well-being and continuous growth of each person who joins our team.  In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew

About the Position

Reporting to the VP of Cell Process R&D, the Director/Sr. Director of Gene Transfer will be responsible for identification, evaluation, and implementation into the CAAR T cell manufacturing process of new and innovative gene transfer technologies. This leadership role will be responsible for managing a small team, interacting with internal research and process development teams and external collaborators, as well as exploring new partnerships for lentiviral production technologies. The role will require up to 10% – 20% travel.

Responsibilities include to:

  • Identify, select, and implement gene transfer methods which improve the efficiency, safety and/or cost of the CAAR T cell manufacturing process.
  • Lead a team to develop optimized lentiviral vector production technologies for gene and cell therapy applications, in collaboration with external production partners.
  • Assist with the transfer of plasmid and lentiviral vector production processes and controls to company designated production partners.
  • Provide technical expertise and support management of the GMP production, testing, and fill finish of lentiviral vectors.
  • Accountable for external GMP plasmid production and characterization for use in vector production.
  • Accountable for external GMP protein and RNA production for alternate gene transfer technologies, as required.
  • Assess partnering/collaboration opportunities to advance pipeline and platform capabilities in gene transfer, and lead proof of concept studies.
  • Produce and provide gene transfer methods and reagents to Cabaletta research staff to enable other areas of scientific and process development study.
  • Provide scientific and process development support and expertise to the cell process development team.
  • Lead and manage daily activities in combination with a team of more junior level staff.

Required Qualifications

  • Ph.D. in Biological Sciences or related fields with 10 + years’ experience working with complex biologics and direct experience working with lentiviral vector development.
  • Proficient knowledge and hands-on experience with various gene editing approaches and technologies.
  • Experience using gene transfer vector systems, specifically lentiviral vector systems.
  • Excellent lab-based skills with particular emphasis on T-cell biological techniques including cell culture, T-cell transfection, viral vector production/purification (especially lentiviral vectors), immunofluorescence and flow cytometry.
  • Knowledge of GMP, GLP, and ICH regulatory guidelines.
  • Highly organized and a proven track record of successful technical knowledge within viral vector research and development.
  • Proven focused and resourceful within areas of novel gene editing technologies.
  • Previous team management experience, including the training of more junior level staff.

Our name – Cabaletta – is derived from the operatic term for the second part of an aria that is designed to highlight the technical expertise of the lead singer. While our company is not the first to develop chimeric T cells as therapies, we are the first to develop them in a way that leverages T cells to specifically eliminate only B cells that cause disease, while sparing healthy B cells. Utilizing the backbone of this core technology, we expect to advance our portfolio with a rapid and repetitive rhythm, similar to the rhythm that is typical of a cabaletta.

For more information, please visit https://www.cabalettabio.com/ or email careers@cabalettabio.com directly to submit an application. Please include your CV along with the title of the position you are applying for.

Our most important asset is our people and we offer competitive benefits, PTO, and stock option plans.

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.